Delayed breast cancer diagnosis can have serious clinical and medico-legal consequences. In this article, we explore the key themes from INNEG’s webinar with Dr Vasileios Angelis, Consultant Medical Oncologist, including breach, causation, treatment burden and expert evidence.

Watch the full webinar with Dr Vasileios Angelis here >

Why Breast Cancer Delay Claims Are Clinically and Legally Significant

Breast cancer is one of the most common cancers in the UK, with tens of thousands of new diagnoses each year. Because the diagnostic pathway often involves multiple professionals, including GPs, radiologists, pathologists, surgeons and oncologists, there are several points where errors can occur.

In medico-legal practice, Dr Angelis explained that many claims arise not from rare or obscure clinical scenarios, but from “bread and butter” failures in a well-established pathway.

These may include:

• Failure to make a two-week-wait referral.
• Failure to report a visible abnormality on mammogram.
• Incorrect pathology reporting.
• Failure to follow up abnormal results.
• Communication failures between clinicians.
• Missed screening abnormalities.

These errors can be particularly significant where the tumour was small, localised and potentially curable at the time of breach, but was later diagnosed at a more advanced stage

Delay in Diagnosis: Clinical Risks

The central clinical issue in many breast cancer claims is whether the delay changed the patient’s outcome.

Dr Angelis described causation as the key battleground. Breach may be easier to identify where a guideline was not followed, an image was misreported, or a biopsy was wrongly interpreted. Causation, however, requires experts to reconstruct what would likely have happened had the patient been diagnosed earlier.

That analysis usually focuses on three questions:

1. Stage progression
   Did the cancer move from a lower stage to a higher stage during the period of delay?
2. Prognosis
   Did that progression reduce survival or increase the risk of recurrence?
3. Treatment burden
   Did the patient require more extensive treatment than they would otherwise have needed?

For solicitors, this means the claim should not focus solely on survival. Avoidable mastectomy, chemotherapy, radiotherapy, axillary clearance, extended endocrine therapy and psychological harm may all be relevant when assessing damages.

“In many breast cancer negligence claims, the strongest causation argument is not only reduced survival, but the treatment burden that comes with delayed diagnosis.”

Breast Cancer Subtypes and Why They Matter

Breast cancer is not a single clinical entity. Different tumour subtypes behave differently, and this can significantly affect causation.

Dr Angelis highlighted three broad categories:

ER-positive / HER2-negative breast cancer
This is the most common subtype and is often slower growing. In some cases, shorter delays may not materially alter prognosis, although treatment burden may still be affected.

HER2-positive breast cancer
This is generally more aggressive and may progress more quickly. A delay may increase the chance of nodal involvement or metastatic spread.

Triple-negative breast cancer
This is also more aggressive and may have a worse prognosis. Even relatively short delays can be clinically significant.

For solicitors, tumour biology is important because it affects the expert’s analysis of growth rate, prognosis and whether earlier diagnosis would probably have changed treatment or outcome.

“Even small delays in HER2-positive and triple-negative breast cancers can lead to significant loss of benefit and survival change.”

Medico-Legal Considerations

A strong breast cancer negligence claim usually depends on a clear timeline and the right expert evidence.

Dr Angelis suggested a practical causation framework:

1. Identify the Breach

The first step is to define the specific failure and the date it occurred. This date becomes the anchor point for the whole causation analysis.

Examples may include:

• A GP failing to refer under NICE NG12.
• A radiologist failing to report a visible abnormality.
• A pathologist incorrectly reporting malignant tissue as benign.
• A failure to act on abnormal results.

2. Reconstruct the Counterfactual

The next question is what a competent clinician would have done at the time. This is often where radiology or pathology evidence is essential.

For example, if a mammogram showed a reportable abnormality, a breast radiologist may be asked to confirm what should have been seen and what should have happened next.

3. Assess the Likely Stage at Breach

This is often where defendants focus their arguments. They may argue that the cancer was already advanced at the time of the alleged negligence.

An oncology expert may need to address this using:

• Imaging evidence.
• Tumour size.
• Growth rate modelling.
• Histology.
• Clinical presentation.
• Timing of symptoms.

4. Compare Prognosis

The expert must compare the likely prognosis at the date of breach with the prognosis at actual diagnosis.

This may include survival, recurrence risk and risk of metastatic disease.

5. Quantify the Treatment Differential

Even where survival is not affected, treatment burden may be highly relevant.

A patient may have avoided:

• Mastectomy.
• Chemotherapy.
• Radiotherapy.
• Axillary node clearance.
• Longer endocrine therapy.
• Newer systemic treatments.
• Additional monitoring and hospital appointments.

“Do not undervalue treatment burden. It can be a significant head of damage even where overall survival is ultimately unaffected.”

Case Examples and Outcomes

Case Example 1: Missed Mammogram Abnormality

Dr Angelis discussed a case involving a 52-year-old woman undergoing routine NHS screening.

At the original screening, a spiculated density was visible but not reported. The patient was not recalled. Later, she presented with a larger tumour, with evidence of stage progression.

The medico-legal issues included:

• Whether the abnormality was visible and reportable.
• Whether recall was required.
• Whether the tumour would probably have been stage one at the original screening.
• Whether earlier diagnosis would have avoided more extensive treatment.

The likely damages included avoidable mastectomy and chemotherapy, alongside the consequences of a worsened prognosis.

Case Example 2: Pathology Error and Metastatic Disease

The second case involved a 47-year-old woman who presented with a breast mass. Imaging was suspicious and a core biopsy was taken. The pathology report incorrectly described the sample as benign fibrocystic change.

Seven months later, the patient returned with a much larger tumour, skin involvement and liver lesions consistent with metastases.

Here, breach was likely established if the original slides clearly showed malignant cells. The more difficult issue was causation: whether metastatic disease was already present at the time of the original biopsy, or whether it developed during the delay.

This distinction is critical. If metastases developed during the delay, the negligence may have transformed a potentially curable case into an incurable one.

Key Takeaways for Solicitors

Breast cancer negligence claims often turn on a small number of clinically important questions:

• When did the negligence occur?
• What should have happened at that point?
• What stage was the tumour likely to be at that time?
• Did the delay cause stage progression?
• Did the delay reduce survival or increase recurrence risk?
• Did the delay increase treatment burden?
• Have the correct experts reviewed the primary evidence?

A clear chronology is essential. On day one, solicitors should aim to map the first symptom, first presentation, investigations, results, treatment decisions and eventual diagnosis.

NICE NG12 may also be an important anchor in referral failure cases, particularly where the clinical presentation met the threshold for urgent referral.

Treatment Burden as a Head of Damage

One of the key messages from the webinar was that solicitors should think beyond survival.

A delayed diagnosis may mean the claimant requires more invasive surgery, more aggressive systemic therapy, longer treatment and greater psychological harm. These issues may remain highly relevant even if the patient survives or if the overall survival difference is contested.

Treatment burden may include:

• Permanent loss of the breast.
• Lymphoedema following axillary clearance.
• Chemotherapy toxicity.
• Extended endocrine therapy.
• Additional targeted therapies.
• More hospital appointments and monitoring.
• Fear of recurrence.
• Psychological impact.

As breast cancer treatments evolve, newer drugs may also become relevant to damages, particularly where delayed diagnosis places a patient into a higher-risk treatment category.

“Earlier diagnosis is associated with a better outcome, no matter what the drugs are.”

Watch the full webinar here >